CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy

CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy

The advent of engineered T cells as a form of immunotherapy marks the beginning of a new era in medicine, providing a transformative way to combat complex diseases such as cancer. Following FDA approval of CAR T cells directed against the CD19 protein for the treatment of acute lymphoblastic leukemi...

Full description

Bibliographic Details
Main Authors: January Salas-Mckee, Weimin Kong, Whitney L. Gladney, Julie K. Jadlowsky, Gabriela Plesa, Megan M. Davis, Joseph A. Fraietta
Format: Article
Language:English
Published: Taylor & Francis Group 2019-05-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
car t cell
crispr/cas9
cancer immunotherapy
genome editing
Online Access:http://dx.doi.org/10.1080/21645515.2019.1571893

Internet

http://dx.doi.org/10.1080/21645515.2019.1571893

Similar Items